The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523, a Syk Inhibitor in Adult Patients of Immune Thrombocytopenia: a Randomized, Double Blinded, Placebo Controlled Phase Ib Study
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Sovleplenib (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Proof of concept
- Acronyms ESLIM-01
- Sponsors Hutchison MediPharma; HUTCHMED
- 16 Jul 2024 Status changed from active, no longer recruiting to completed.
- 21 Aug 2023 Results presented in the HUTCHMED media release
- 31 Jul 2023 According to a HUTCHMED media release, the company expects to report top-line result in 2023.